^
    Apply
    An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors (NCT02038673)
    Phase 1
    Astellas Pharma Inc
    Completed
    Last update posted :
    10/22/2018
    Initiation :
    11/05/2013
    Primary completion :
    07/19/2017
    Completion :
    07/19/2017
    FGF19 • FGF23
    |
    ASP5878